摘要
目的:观察分析恩替卡韦治疗老年失代偿期乙肝后肝硬化的效果和不良反应情况。方法:选取笔者所在医院80例老年失代偿期乙肝后肝硬化患者,采用随机数字表法分为对照组和观察组,各40例。对照组患者采用常规的护肝、保肝治疗方式进行治疗,观察组患者在此基础上使用恩替卡韦进行治疗,比较两组治疗的效果和不良反应情况。结果:经过治疗后两组患者的肝功都能得到改善,观察组的临床疗效和TBi L、ALT、AST等指标改善情况均明显优于对照组,两组比较差异均有统计学意义(P<0.05);观察组和对照组不良反应发生率差异不大,比较差异无统计学意义(P>0.05)。结论:恩替卡韦治疗老年代偿期乙肝后肝硬化具有明显的效果,不良反应轻微,安全性较好,值得推广。
Objective： To observe and analyse the effects of entecavir treatment in elderly patients with decompensated liver cirrhosis and the adverse reactions.Method： 80 cases of elderly patients with decompensated liver cirrhosis were selected in our hospital and divided into the control group and observation group by random number table method, 40 cases in each group, the control group were treated by liver protection and liver treatments on the basis of routine treatment, the observation group patients were taked entecavir treatment on the basis of the control group, compared two groups of treatment effect and adverse reactions.Result： After treatment, liver function in patients of two groups could be improved and the clinical curative effect, TBiL, ALT, AST and other indicators of observation group were significantly better than the control group, there were statistically significant（P〈0.05）. Difference of observation group and control group in incidence of adverse reactions, there was no statistical significance（P〉0.05）.Condusion： Entecavir treatment of elderly patients with compensatory phase cirrhosis after hepatitis b has obvious effect, adverse reaction is mild, security is good, and it is worth promoting.
出处
《中外医学研究》
2015年第33期11-12,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
恩替卡韦
老年失代偿期乙肝后肝硬化
疗效
不良反应
Entecavir
Elderly deeompensated liver cirrhosis after hepatitis B
Curative effect
Adverse reactions
